News
President Trump escalated pressure on the pharmaceutical industry last week by sending letters to 17 major drug companies ...
Pfizer's Albert Bourla told investors that major drugmakers are "ready to to roll up their sleeves" and build out more direct ...
Risk assessment for potential mutagenic side-products is still required by regulatory bodies, despite lack of evidence they ...
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 ...
And pharmaceutical companies spend big on lobbying in Washington — more than any other industry in 2017 — helping to assure victories like the 2003 Medicare Part D legislation which banned the ...
The pharmaceutical sector, a beacon of innovation, stands tall in Europe's economic landscape. Yet even a robust industry is not immune to financial challenges.
The Canadian pharmaceutical industry is still waiting to learn about tariffs as high as 200 per cent on exports to the U.S.
GlobalData on MSN1d
Pharma CEOs downplay impact of tariffs amid rising cost concernsAnalysis by GlobalData characterises an uncertain pharma landscape, though big pharma CEOs allay investor concern.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback